Literature DB >> 9778247

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

F Saudou1, S Finkbeiner, D Devys, M E Greenberg.   

Abstract

The mechanisms by which mutant huntingtin induces neurodegeneration were investigated using a cellular model that recapitulates features of neurodegeneration seen in Huntington's disease. When transfected into cultured striatal neurons, mutant huntingtin induces neurodegeneration by an apoptotic mechanism. Antiapoptotic compounds or neurotrophic factors protected neurons against mutant huntingtin. Blocking nuclear localization of mutant huntingtin suppressed its ability to form intranuclear inclusions and to induce neurodegeneration. However, the presence of inclusions did not correlate with huntingtin-induced death. The exposure of mutant huntingtin-transfected striatal neurons to conditions that suppress the formation of inclusions resulted in an increase in mutant huntingtin-induced death. These findings suggest that mutant huntingtin acts within the nucleus to induce neurodegeneration. However, intranuclear inclusions may reflect a cellular mechanism to protect against huntingtin-induced cell death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778247     DOI: 10.1016/s0092-8674(00)81782-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  425 in total

1.  Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein.

Authors:  J Doostzadeh-Cizeron; R Evans; S Yin; D W Goodrich
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

Review 2.  Molecular mechanisms regulating motor neuron development and degeneration.

Authors:  T J Kilpatrick; M Soilu-Hänninen
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

3.  Evidence for a protein mutator in yeast: role of the Hsp70-related chaperone ssb in formation, stability, and toxicity of the [PSI] prion.

Authors:  Y O Chernoff; G P Newnam; J Kumar; K Allen; A D Zink
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

Review 4.  Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.

Authors:  A Lunkes; Y Trottier; J Fagart; P Schultz; G Zeder-Lutz; D Moras; J L Mandel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 5.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 6.  Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.

Authors:  A S Hackam; J G Hodgson; R Singaraja; T Zhang; L Gan; C A Gutekunst; S M Hersch; M R Hayden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 7.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 8.  The localization and interactions of huntingtin.

Authors:  A L Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

9.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

10.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.